Recordati SpA Az nom Post raggruppamento REC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €52.85
- Day Range
- €52.85–52.95
- 52-Week Range
- €43.76–53.80
- Bid/Ask
- €52.80 / €53.00
- Shares Outstanding
- 208.14M
- Market Cap
- €11.00B
- Volume/Avg
- 438,105 / 429,896
Key Statistics
- Price/Earnings (Normalized)
- 19.08
- Price/Sales
- 3.99
- Dividend Yield (Trailing)
- 2.54%
- Dividend Yield (Forward)
- 2.69%
- Dividend Payment Schedule
- May, Nov
- Total Yield
- 2.54%
Company Profile
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Core
- Total Number of Employees
- 4,700
- Website
- https://www.recordati.com
Valuation
Metric | REC |
|---|---|
Price/Earnings (Normalized) | 19.08 |
Price/Book Value | 4.70 |
Price/Sales | 3.99 |
Price/Cash Flow | 13.46 |
Price/Earnings
REC
Financial Strength
Metric | REC |
|---|---|
Quick Ratio | 0.91 |
Current Ratio | 1.34 |
Interest Coverage | 8.11 |
Quick Ratio
REC
Profitability
Metric | REC |
|---|---|
Return on Assets (Normalized) | 12.78% |
Return on Equity (Normalized) | 32.90% |
Return on Invested Capital (Normalized) | 17.02% |
Return on Assets
REC
Drug Manufacturers - General Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|<g<lHM?$ | LOCK|?V@ | $1T | |||
| Johnson & Johnson JNJ | LOCK|Zh@%L$g | LOCK|yj | $680B | |||
| AbbVie Inc ABBV | LOCK|gCcn!$X | LOCK|Y!% | $521B | |||
| Roche Holding AG ADR RHHBY | LOCK|$P&BRdW | LOCK|n%W | $389B | |||
| Merck & Co Inc MRK | LOCK|hb^?$%< | LOCK|%! | $356B | |||
| Novartis AG ADR NVS | LOCK|?Lz&lRrz | LOCK|$RH | $306B | |||
| AstraZeneca PLC AZN | LOCK|PVKm&M&> | LOCK|wY | $288B | |||
| Amgen Inc AMGN | LOCK|>G<VnXH | LOCK|ZC | $250B | |||
| Gilead Sciences Inc GILD | LOCK|j%!^dF& | LOCK|P$> | $208B | |||
| Novo Nordisk AS ADR NVO | LOCK|Nb?Sr? | LOCK|!^ | $185B |